Who Is the Next Chlorfenapyr? — Jinlong Zhang

Brazil’s pesticide market nearly tripled in fifteen years. One molecule went 28× in five. This talk asks a simple question: what comes next — and how do you screen for it before the volume chart tells everyone?

1 · The market

Pesticide use: 307 kt (2009) → 908 kt (2024), CAGR 7.5%. Herbicides are over half of it.
Mato Grosso alone takes 24.9% of volume; MATOPIBA and its surroundings keep gaining share.
Direct formulation imports have doubled to 0.8–1.0 Mt — import demand has shifted from technical-led to formulation-led.

2 · The star

Chlorfenapyr: 28.5× in five years (2019→2024, CAGR 95.4%). From 25th among Brazilian insecticides to 4th.
2025 import check: the top five importers took 49,261 t — 93.6% of the flow; local formulators keep buying technical abroad.
Chinese technical price fell 52% in two years to RMB 115k/t — but price is a necessary condition, not a sufficient one. Everything was getting cheaper; only chlorfenapyr exploded.

3 · Four conditions — all required

Independent mechanism. Its IRAC group (13) sits outside the top three groups used in that crop programme — no cross-resistance, so it earns a rotation slot by default.

A resistance gap already visible. A leading active in the target class fell more than 15% for two years running — not a theoretical risk, a measured one.

An area step-change. From cotton and vegetables into the soybean programme: treated area jumps an order of magnitude.

A price that lets the volume jump. The whole industry was falling; the winner is the one whose price fall met the gap.

4 · Three candidates, three windows

Pyriproxyfen → window 2026–2027. The closest match in shape: five-year CAGR 55.9%, 2024 single year +228%, import dependence 44.8%.
Fluopyram → 2028. The largest space: use patent expires 2028, 2021→2024 +587%, annual nematode loss around BRL 35 bn.
Pyroxasulfone → 2030. The strongest resistance push: sourgrass widely glyphosate-resistant, no post-emergence option left, soybean penetration under 5%.

5 · Three caveats — where this can be wrong

Cycle. 2024 was a restocking year, 2025 set another record — 2026 is falling by double digits. The candidate must beat the market, not the base year.
People. Scaling depends on the promoter: the first generic registrants decide whether the volume jumps.
Regulation. Registration speed, HSE risk assessment, and bans or restrictions in major markets can reshape the window.

What I can offer

Product screening and feasibility — the same six-rule screen, applied to your portfolio.
Formulation choice and registration pathway.
Compliance upgrade, quality and EHS, freedom-to-operate (IP).

Full deck available on request: jinlong.zhang@vcsabio.com